Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity

Acta Oncol. 2020 Apr;59(4):484-489. doi: 10.1080/0284186X.2020.1723163. Epub 2020 Mar 3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Bortezomib / adverse effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Polyradiculoneuropathy / chemically induced
  • Polyradiculoneuropathy / pathology*
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Bortezomib